Three San Diego life science firms reported earnings for the fourth quarter and full 2015 year this week.

Mast Therapeutics Inc.

Mast Therapeutics Inc., a biopharmaceutical company in San Diego developing therapies for sickle cell disease and heart failure, reported a net loss of $39.8 million for 2015, compared to a net loss of $28.7 million in 2014.

Research and development expenses for the year were $28.3 million, an increase of $8.9 million, or 45 percent, compared to $19.4 million for the same period in 2014. The increase was mainly due to fees and expenses relating to development and manufacturing of the company’s lead asset, vepoloxamer, along with costs associated with the company’s EPIC study.

The company reported a net loss of $10.2 million for the fourth quarter of 2015, compared to a net loss of $7.3 million for the same period in 2014.

Research and development expenses for the fourth quarter of 2015 were $7.2 million, compared to $4.9 million for the same period in 2014.

Biocept Inc.

San Diego-based Biocept Inc., a company making liquid biopsies to improve the detection and treatment of cancer, reported a net loss of $16.9 million for 2015, compared to a net loss of $15.9 million for 2014. Revenues for 2015 reached $610,000, a $477,000 increase from 2014.

Biocept reported a net loss of $4.6 million for the fourth quarter of 2015, compared to a net loss of $3.9 million for the same period the previous year. The increase in net loss was primarily due to higher expenses associated with the overall growth of the business and the expansion of the sales and marketing departments, according to a Biocept news release.

Mirati Therapeutics Inc.

San Diego-based Mirati Therapeutics Inc., a company developing medicines for targeted oncology, reported a net loss for the fourth quarter of 2015 of $18.4 million, compared to a net loss of $10.4 million for the same period in 2014. Net loss for the year ending Dec. 31, 2015, was $64.5 million, compared to a net loss of $43.7 million for the same period in 2014.

Research and development expenses for the fourth quarter of 2015 were $14.9 million, compared to $7.1 million for the same period in 2014. Research and development expenses for the year ending Dec. 31, 2015, were $49 million, compared to $26.1 million for the same period in 2014. The increases in research and development expenses primarily reflect costs to advance the clinical development of the company's three oncology development programs, MGCD265, MGCD516 and mocetinostat.

Cash, cash equivalents, and short-term investments were $122.3 million as of Dec. 31, 2015, compared to $29.3 million as of Dec. 31, 2014. In September 2015, Mirati completed a public offering of its common stock, generating net proceeds of $94.9 million. In February 2015, the company completed a public offering of 2.6 million shares of its common stock, generating net proceeds of $48.4 million.